


## SL-54. Inhibitors of Menin-MLL Interaction

Chromosomal translocations in the mixed lineage leukemia gene (MLL) are observed in many patients diagnosed with acute myeloid leukemia [1]. A potential therapeutic strategy for MLL1-dependant leukemia is to block the interaction between menin and MLL using small molecule ligands [1]. Discovery of drug-like, high-affinity small molecule inhibitors of the menin-MLL interaction with an appropriate pharmacological profile for clinical

development is a significant challenge [2]. MI-503 (below) is a recently reported lead compound demonstrating substantial *in vivo* efficacy in animal models [2].

A 2D similarity search through ASINEX's compound collection has resulted in several thienopyrimidine-based analogs, close analogs of MI-503. Such analogs could be interesting chemical probes for MLL-directed research.



### Signature Library 54

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 μmol; 1 μmol DMSO solutions	SL#54_Menin-MLL.sdf

#### References:

1. *Exp Hematol*. 2014 December; 42(12): 995–1012. doi:10.1016/j.exphem.2014.09.006
2. *Cancer Cell* 27, 589–602; April 13, 2015. 10.1016/j.ccell.2015.02.016

#### Contact us:

USA: +1 336 721 1617  
Japan: +81-80-3401-9097  
Europe/Global:

[mparisi@asinex.com](mailto:mparisi@asinex.com)  
[sota@asinex.com](mailto:sota@asinex.com)  
[lsadovenko@asinex.com](mailto:lsadovenko@asinex.com)